

■ **Sinovac's coronavirus vaccine* induces coronavirus-neutralising antibodies and is a promising development in SARS prevention,**** according to preliminary results from a phase I study. In this study, 36 healthy volunteers were randomised to receive two doses of a coronavirus vaccine (n = 24) or placebo, 28 days apart. After the preliminary 56-day observation period, blood serum conversion was observed in 11 of 12 and 12 of 12 subjects who received high and low doses of the vaccine, respectively. The antibody serum conversion rates were 50% and 100% at days 35 and 42, respectively.

* Sinovac Biotech; phase I for coronavirus infections in China

** severe acute respiratory syndrome

Sinovac Biotech Ltd. Sinovac Biotech Ltd. Releases Further Results From SARS Vaccine Phase I Human Clinical Trial. Media Release : 13 Dec 2004.
Available from: URL: <http://www.sinovac.com> 809042979